Cholesterol reduces the sensitivity to platinum-based chemotherapy via upregulating ABCG2 in lung adenocarcinoma
Yufeng Wu(Peking University), Qiming Wang(Hunan Cancer Hospital), Lili Wang(Zhengzhou University), Yingchao Fan(Shanghai Jiao Tong University), Zhen He(Military Hospital), Suhua Xia(Soochow University), Zelai He(First Affiliated Hospital of Bengbu Medical College), Hong Tang(First Affiliated Hospital of Jiangxi Medical College), Hui Zhu(Sun Yat-sen University), Ruirui Si(Tongji University)
Cited by 55
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311
MEK inhibitors for the treatment of non-small cell lung cancer
|Journal of Hematology & Oncology|2021|300
α-Synuclein in salivary extracellular vesicles as a potential biomarker of Parkinson’s disease
|Neuroscience Letters|2018|161